


CLAIMS

1. A compound of formula (I):




wherein:



B is alkylene, -alkylene-(O)-, -alkylene-N(R)C(O)-, -alkylene-(heterocyclyl)-C(O)-, -alkylene-C(O)N(R)-, -alkylene-C(O)-, -alkylene-N(R)-, -alkylene-N(R)C(O)N(R)-, -alkylene-N(R)SO₂-, -alkylene-(aryl)-, -alkylene-(heterocyclyl)-, -alkylene-(heterocyclyl)-alkylene-, -aryl-alkylene-N(R)C(O)-; -aryl-C(O)N(R)-, -aryl-N(R)C(O)-, -(heterocyclyl)-alkylene-, -heterocyclyl-alkylene-N(R)C(O)-; -heterocyclyl-C(O)N(R)-, -O-heterocyclyl-; -alkylene-O-; -heterocyclyl-C(O)-; cycloalkylene; or cycloalkylene-O-;

10





R is H, alkyl, or aryl;

R₁ is independently H, alkyl, halide, alkoxy, CF₃, OH, alkylene-OH, NO₂, -N(H)R, or NH₂;

15

R₂ is H, alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, cycloalkyl, -alkylene-alkoxy, alkylene-aryl, or heterocycloalkyl;

 , and  are a 3-12 membered heterocycloalkylene unsubstituted or substituted by one or more instance of R₁;

X is C(R_c) or N;


both instances of R_a are H, or taken together form a bond, or a (C₁-C₄)alkylene bridge;

R_b is H, or (C₁-C₆)alkyl; and

5 R_c is H, alkyl, aryl, OH, or halide;


or a pharmaceutically acceptable salt thereof;

provided that the compound of formula (I) is not




10

2. The compound of claim 1, wherein




3. The compound of claim 1, wherein
15 membered heterocycloalkylene.



is an unsubstituted 3-12

4. The compound of any one of claims 1-3, wherein at least one instance of R₁ is alkyl, halide, OMe, OH, alkylene-OH, or NH₂.
5. The compound of claim 4, wherein R₁ is alkyl, or halide.
6. The compound of any one of claims 1-3, wherein all instances of R₁ are H.
- 5 7. The compound of any one of claims 1-6, wherein B is selected from the group consisting of:



R is Me, or Ph;


m is 0, 1, 2, or 3;

n is 0, or 1; and


p is 0, 1, or 2.

8. The compound of any one of claims 1-7, wherein X is N.


9. The compound of claim 8, wherein C is selected from the group consisting of:




10. The compound of any one of claims 1-7, wherein X is $C(R_c)$.



11. The compound of claim 10, wherein C is



12. The compound of claim 10, wherein:



R_3 , R_6 , and R_7 are independently H, halide, CF_3 , alkyl, alkylene-alkoxy, aryl, hydroxyl, or alkoxy; and

10 n' is independently 0, 1, or 2.

13. The compound of claim 12, wherein at least one instance of n' is 0.

14. The compound of claim 12, wherein at least one instance of n' is 1.


15. The compound of claim 12, wherein at least one instance of n' is 2.

16. The compound of claim 12, wherein one instance of n' is 0, and one instance of n' is 1.


15 17. The compound of any one of claims 12-16, wherein R_3 is H, halide, Me, OMe, or Ph.

18. The compound of any one of claims 12-17, wherein R_6 is H; and R_7 is H, or CH_2OH .

19. The compound of claim 12, wherein C is selected from the group consisting of:




20. The compound of claim 10, wherein:



5 R₃, R₆, and R₇ are independently H, halide, CF₃, alkyl, alkylene-alkoxy, aryl, hydroxyl, or alkoxy; and

n' is independently 0, 1, or 2.



21. The compound of claim 20, wherein C is

22. The compound of any one of claims 1-21, wherein R₂ is H, (C₁-C₄)alkyl, cyclopropyl, CH₂OMe, phenyl, -CH₂Ph, pyridinyl, or indolyl.

23. The compound of claim 22, wherein R₂ is H.

24. The compound of claim 22, wherein R₂ is Me.

25. The compound of claim 22, wherein R₂ is unsubstituted phenyl.

26. The compound of claim 22, wherein R₂ is substituted phenyl.

15 27. The compound of claim 26, wherein the substituted phenyl is substituted with one or more independent instances of alkoxy, OH, halide, -N(H)C(O)alkyl, -C(O)NH₂, or -C(O)alkyl.

28. The compound of claim 27, wherein the substituted phenyl is substituted with at least one halide.


29. The compound of claim 28, wherein the halide is Cl.

30. The compound of claim 22, wherein R₂ is unsubstituted pyridinyl.


31. The compound of claim 22, wherein R₂ is substituted pyridinyl.

32. The compound of claim 31, wherein the substituted pyridinyl is substituted with NH₂,
5 or OH.











33. The compound of claim 22, wherein R₂ is












34. The compound of any one of claims 1-3 and 6-33, wherein A is













35. The compound of claim 1, wherein the compound is selected from the group consisting
of:


























10















5















5















10




5













10












5














5







36. The compound of claim 1, wherein the compound is selected from the group consisting of:
























- 5 37. The compound of claim 1, wherein the compound is selected from the group consisting of:






5




5



38. The compound of claim 1, wherein the compound is selected from the group consisting of:


10




and

5







40. The compound of claim 1, wherein the compound is selected from the group consisting




41. The compound of claim 1, wherein the compound is selected from the group






5




5




5






42. The compound of claim 1, wherein the compound is selected from the group





consisting of:




5



















5





43. The compound of claim 1, wherein the compound is selected from the group








5





induced fibrosis, coagulation-induced fibrosis, vascular injury-induced fibrosis, aortic stenosis, and cardiac fibrosis.

46. The compound for use of claim 45, wherein the disease or condition is a solid tumor.

47. The compound for use of claim 46, wherein the solid tumor is selected from the group

5 consisting of Ewing's sarcoma, rhabdomyosarcoma, osteosarcoma, myelosarcoma, chondrosarcoma, liposarcoma, leiomyosarcoma, soft tissue sarcoma, non-small cell lung cancer, small cell lung cancer, bronchus cancer, prostate cancer, breast cancer, pancreatic cancer, gastrointestinal cancer, colon cancer, rectum cancer, colon carcinoma, colorectal adenoma, thyroid cancer, liver cancer, intrahepatic bile duct
10 cancer, hepatocellular cancer, adrenal gland cancer, stomach cancer, gastric cancer, glioma (e.g., adult, childhood brain stem, childhood cerebral astrocytoma, childhood visual pathway and hypothalamic), glioblastoma, endometrial cancer, melanoma, kidney cancer, renal pelvis cancer, urinary bladder cancer, uterine corpus, uterine cervical cancer, vaginal cancer, ovarian cancer, multiple myeloma, esophageal cancer,
15 brain cancer (e.g., brain stem glioma, cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, meduloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma), lip and oral cavity and pharynx, larynx, small intestine, melanoma, villous colon adenoma, a neoplasia, a neoplasia of epithelial character, lymphomas (e.g., AIDS-related, Burkitt's, cutaneous
20 T-cell, Hodgkin, non-Hodgkin, and primary central nervous system), a mammary carcinoma, basal cell carcinoma, squamous cell carcinoma, actinic keratosis, tumor diseases, including solid tumors, a tumor of the neck or head, polycythemia vera, essential thrombocythemia, myelofibrosis with myeloid metaplasia, Waldenstrom's macroglobulinemia, adrenocortical carcinoma, AIDS-related cancers, childhood
25 cerebellar astrocytoma, childhood cerebellar astrocytoma, basal cell carcinoma, extrahepatic bile duct cancer, malignant fibrous histiocytoma bone cancer, bronchial adenomas/carcinoids, carcinoid tumor, gastrointestinal carcinoid tumor, primary central nervous system, cerebellar astrocytoma, childhood cancers, ependymoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer,
30 intraocular melanoma eye cancer, retinoblastoma eye cancer, gallbladder cancer, gastrointestinal carcinoid tumor, germ cell tumors (e.g., extracranial, extragonadal, and ovarian), gestational trophoblastic tumor, hepatocellular cancer, hypopharyngeal cancer, hypothalamic and visual pathway glioma, islet cell carcinoma (endocrine pancreas),

- laryngeal cancer, malignant fibrous histiocytoma of bone/osteosarcoma, medulloblastoma, mesothelioma, metastatic squamous neck cancer with occult primary, multiple endocrine neoplasia syndrome, multiple myeloma/plasma cell neoplasm, mycosis fungoides, nasal cavity and paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oral cancer, oropharyngeal cancer, ovarian epithelial cancer, ovarian germ cell tumor, ovarian low malignant potential tumor, islet cell pancreatic cancer, parathyroid cancer, pheochromocytoma, pineoblastoma, pituitary tumor, pleuropulmonary blastoma, ureter transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Sezary syndrome, non-melanoma skin cancer, Merkel cell carcinoma, squamous cell carcinoma, testicular cancer, thymoma, gestational trophoblastic tumor, and Wilms' tumor.
48. The compound for use of claim 45, wherein the disease or condition is a hematological tumor.
49. The compound for use of claim 48, wherein the hematological tumor is selected from the group consisting of acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma.
50. The compound for use of claim 45, wherein the disease or condition is selected from the group consisting of idiopathic pulmonary fibrosis, systemic sclerosis associated interstitial lung disease, myositis associated interstitial lung disease, systemic lupus erythematosus associated interstitial lung disease, rheumatoid arthritis, and associated interstitial lung disease.
51. The compound for use of claim 45, wherein the disease or condition is selected from the group consisting of diabetic nephropathy, focal segmental glomerulosclerosis, and chronic kidney disease.
52. The compound for use of claim 45, wherein the disease or condition is selected from the group consisting of nonalcoholic steatohepatitis, primary biliary cholangitis, and primary sclerosing cholangitis.